Sarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
May 7, 2015 11:22 AM EDTNeedham & Company reiterate their Buy rating on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with the price target set $38 while awaiting the NDA filing and approval of Eteplirsen.
Needham & Company analyst, Chad Messer, commented on SRPT, saying, "A pre-NDA meeting with the FDA... More
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
May 7, 2015 7:47 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).
Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More